Merck, Keytruda
Merck's colorectal cancer therapy fails late-stage trial
Merck said on Wednesday a combination of its experimental drug and blockbuster therapy Keytruda failed a late-stage trial testing it in previously treated patients with a type of colorectal cancer. Th
Merck’s Keytruda Combo Fails in Phase III Colorectal Cancer Study
Merck follows in the footsteps of Bristol Myers Squibb, which in December 2023 also failed to secure a late-stage victory for its combo regimen of a PD-1 blocker and an anti-LAG-3 antibody.
Merck's Keytruda-LAG-3 combo fails to tame tough colorectal cancer in phase 3
An attempt by Merck & Co. to unlock the microsatellite stable (MSS) metastatic colorectal cancer market has ended in failure. | An attempt by Merck & Co. to unlock the microsatellite stable metastatic colorectal cancer market has ended in failure.
Merck's Experimental Favezelimab/Keytruda Combo Fails In Late-Stage Colorectal Cancer Study
Merck & Co Inc (NYSE:MRK) released topline data from the KEYFORM-007 Phase 3 study of the fixed-dose combination of favezelimab and pembrolizumab versus the standard of care for pretreated patients with microsatellite-stable (MSS) metastatic colorectal cancer (mCRC).
Merck fails in late-stage trial for Keytruda combo in colon cancer
Merck (MRK) stock is in focus as a Phase 3 trial for its cancer drug Keytruda in colorectal cancer patients did not meet primary endpoint. Read more here.
Miss for Merck’s favezelimab combo in colorectal cancer
Merck's Phase III KEYFORM-007 trial, testing a combination of favezelimab and Keytruda, failed to meet its primary endpoint of improving overall survival in patients with metastatic colorectal cancer.
Merck: Favezelimab/Keytruda Combo Study Misses Goal in Colorectal Cancer
Merck is studying Keytruda, a cancer drug that harnesses a patient's immune system to fight tumors, in a raft of trials across a wide variety of cancers and treatment settings. The company is evaluating the Keytruda/favezelimab combination across multiple solid tumor types and in patients with relapsed or refractory classical Hodgkin lymphoma.
MRK's Keytruda Combo Fails in Phase III Colorectal Cancer Study
Merck MRK announced data from the phase III KEYFORM-007 study, which evaluated a fixed-dose combination of its anti-LAG-3 antibody, favezelimab and its blockbuster anti-PD-1 therapy, Keytruda in pre-treated patients with PD-L1 positive microsatellite stable (MSS) metastatic colorectal cancer (mCRC).
BioSpace11d
Despite Win Over Keytruda, Summit’s NSCLC Bispecific Still Has Something to Prove
Summit Therapeutics’ ivonescimab has the potential to challenge Merck’s blockbuster checkpoint inhibitor in non-small cell ...
MedPage Today4d
Cancer Treatment Ups CV Risk; Therapy's Next Big Thing; Nude Photos Settlement
A phase III trial of the fixed-dose combination of the LAG-3 inhibitor favezelimab and pembrolizumab (Keytruda) failed to ...
Merck Says Phase 3 KEYFORM-007 Study Did Not Meet Primary Goal Of Overall Survival
Merck & Co Inc. (MRK) on Wednesday said its Phase 3 KEYFORM-007 study evaluating the company's drug candidate favezelimab in ...
This Stock Is Crushing Nvidia's Performance This Year: Is It Too Late to Buy?
Few companies have attracted more attention this year than Nvidia. The chipmaker is on a roll thanks to the rapid rise of ...